image
Healthcare - Biotechnology - NASDAQ - US
$ 1.335
0 %
$ 303 M
Market Cap
-5.73
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one GOSS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.33 USD, Gossamer Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one GOSS stock under the base case scenario is HIDDEN Compared to the current market price of 1.33 USD, Gossamer Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one GOSS stock under the best case scenario is HIDDEN Compared to the current market price of 1.33 USD, Gossamer Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GOSS

image
$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.715 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
115 M REVENUE
0.00%
-59.9 M OPERATING INCOME
67.39%
-56.5 M NET INCOME
68.56%
-3.47 M OPERATING CASH FLOW
97.82%
29 M INVESTING CASH FLOW
126.15%
-11.5 M FINANCING CASH FLOW
-6.04%
9.89 M REVENUE
5.44%
-36.8 M OPERATING INCOME
-1.89%
-36.6 M NET INCOME
-10.93%
-39.7 M OPERATING CASH FLOW
-11.96%
22.1 M INVESTING CASH FLOW
-58.54%
504 K FINANCING CASH FLOW
0.00%
Balance Sheet Gossamer Bio, Inc.
image
Current Assets 310 M
Cash & Short-Term Investments 295 M
Receivables 5.54 M
Other Current Assets 9.83 M
Non-Current Assets 5.4 M
Long-Term Investments 0
PP&E 5.12 M
Other Non-Current Assets 283 K
93.41 %3.12 %Total Assets$315.3m
Current Liabilities 45 M
Accounts Payable 2.32 M
Short-Term Debt 961 K
Other Current Liabilities 41.7 M
Non-Current Liabilities 241 M
Long-Term Debt 202 M
Other Non-Current Liabilities 38.9 M
14.60 %70.65 %13.60 %Total Liabilities$285.8m
EFFICIENCY
Earnings Waterfall Gossamer Bio, Inc.
image
Revenue 115 M
Cost Of Revenue 0
Gross Profit 115 M
Operating Expenses 175 M
Operating Income -59.9 M
Other Expenses -3.39 M
Net Income -56.5 M
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)115m0115m(175m)(60m)3m(57m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-52.24% OPERATING MARGIN
-52.24%
-49.28% NET MARGIN
-49.28%
-191.67% ROE
-191.67%
-17.93% ROA
-17.93%
-22.45% ROIC
-22.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Gossamer Bio, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -56.5 M
Depreciation & Amortization 4.15 M
Capital Expenditures 0
Stock-Based Compensation 20.6 M
Change in Working Capital 39.5 M
Others 29.9 M
Free Cash Flow -3.47 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Gossamer Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for GOSS of $5.4 , with forecasts ranging from a low of $2 to a high of $12 .
GOSS Lowest Price Target Wall Street Target
2 USD 49.81%
GOSS Average Price Target Wall Street Target
5.4 USD 304.49%
GOSS Highest Price Target Wall Street Target
12 USD 798.88%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Gossamer Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.26 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
324 K USD 3
9-12 MONTHS
7. News
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenheimer Yasmeen Rahimi - Piper Sandler & Co. Paul Choi - Goldman Sachs Olivia Brayer - Cantor Patrick Trucchio - HC Wainwright Laura Chico - Wedbush Operator Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 2025 Earnings Call. I will now turn the program over to Bryan Giraudo, Chief Financial Officer and Chief Operating Officer. seekingalpha.com - 1 month ago
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates Gossamer Bio (GOSS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago. zacks.com - 1 month ago
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2025, and announced the closure of new patient screening for the ongoing registrational Phase 3 PROSERA Study. businesswire.com - 1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio. businesswire.com - 1 month ago
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, Califor. businesswire.com - 1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option. businesswire.com - 2 months ago
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. zacks.com - 3 months ago
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “As we close the book on 2024 and embrace the promise of 2. businesswire.com - 3 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective March 5, 2025, to five non-executive employees of non-qualified stock opti. businesswire.com - 3 months ago
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM. seekingalpha.com - 4 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective February 5, 2025, to three non-executive employees of non-qualified stock option. businesswire.com - 4 months ago
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February. businesswire.com - 4 months ago
8. Profile Summary

Gossamer Bio, Inc. GOSS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 303 M
Dividend Yield 0.00%
Description Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Contact 3013 Science Park Road, San Diego, CA, 92121 https://www.gossamerbio.com
IPO Date Feb. 8, 2019
Employees 144
Officers Mr. Jeff Boerneke General Counsel & Secretary Dr. Robert F. Roscigno Ph.D. Senior Vice President of Clinical Development of Pulmonary Vascular Disease Mr. Christian Waage J.D. Executive Vice President of Technical Operations & Administration Mr. Matt Cravets Senior Vice President of Biometrics Ms. Caryn L. Peterson Executive Vice President of Regulatory Affairs Ms. Jeanine Anthony Senior Vice President of Marketing Ms. Deanna Weber Senior Vice President of Human Resources Mr. Faheem Hasnain Co-Founder, Chief Executive Officer, President & Chairman Mr. Bryan Giraudo Chief Operating Officer & Chief Financial Officer Dr. Richard Aranda M.D. Chief Medical Officer